Phospho-IRAK1 (Thr209) Polyclonal Antibody, Cy7 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-3193R-Cy7-100uL |
| Product Name | Phospho-IRAK1 (Thr209) Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF
|
| Specificity | This phosphorylation site is homologous to Thr209 in Mouse and Rat. |
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human IRAK1 around the phosphorylation site of Thr209 [RG(p-T)HN] |
| Modification Site | Thr209 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 3654 |
| Swiss Prot | P51617 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | IRAK; pelle; Interleukin-1 receptor-associated kinase 1; IRAK-1; IRAK1 |
| Background | Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF | FCM1:20-100 |
Frequently asked questions
Which applications is Phospho-IRAK1 (Thr209) Polyclonal Antibody, Cy7 Conjugated (bs-3193R-Cy7) validated for, and at what dilution?
bs-3193R-Cy7 is validated for WB (1:300-5000); FCM (1:20-100); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does Phospho-IRAK1 (Thr209) Polyclonal Antibody, Cy7 Conjugated (bs-3193R-Cy7) react with?
Tested reactivity: Human, Mouse, Rat.
How should bs-3193R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Phospho-IRAK1 (Thr209) Polyclonal Antibody, Cy7 Conjugated (bs-3193R-Cy7)?
KLH conjugated synthetic phosphopeptide derived from human IRAK1 around the phosphorylation site of Thr209 [RG(p-T)HN]
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-3193R-Cy7)?
Cy7 on bs-3193R-Cy7: excitation / emission 743nm/767nm.